Pharmaceutical

 Strategies to Increase the Value of Drug Therapy

Strategies to Increase the Value of Drug Therapy

Value is a concept that concerns all healthcare stakeholders.

Five things for pharma marketers to know: Monday, April 27

Five things for pharma marketers to know: Monday, April 27

By

More pharma companies hike drug prices post-acquisition; HCV linked to increased risk of cancer; a combined Teva-Mylan would control 25% of the US generic drug market

Tecfidera sales slow, Biogen to maintain "significant" sales force

Tecfidera sales slow, Biogen to maintain "significant" sales force

By

The drugmaker said its top-selling multiple-sclerosis drug Tecfidera's slowdown in sales is due to competition from Plegridy as well as new patient concerns about risks of a rare brain infection.

Five things for pharma marketers to know: Friday, April 24

Five things for pharma marketers to know: Friday, April 24

By

An AbbVie hep.-C drug nabbed priority review; Merck's hep.-C drug matches efficacy of Harvoni; Mylan increased its bid to buy Perrigo

Merck HCV med's efficacy matches competitors'

Merck HCV med's efficacy matches competitors'

By

The drugmaker touted new data for its doublet regimen at the International Liver Congress, but it will likely have to look to the margins to find an underserved patient population.

FDA grants Pfizer lung-cancer drug Breakthrough Designation

Xalkori received the designation to treat a new subset of non-small cell lung cancer patients.

Five things for pharma marketers to know: Wednesday, April 22

Five things for pharma marketers to know: Wednesday, April 22

By

Study finds vaccines still not linked to autism; investments in healthcare start-ups hit record high this year; biosimilars are already bearing down on prices overseas

Merck files Keytruda for lung cancer, eyes first-line niche

Merck files Keytruda for lung cancer, eyes first-line niche

By

Genetic protein PD-L1 could have potential as a biomarker for a first-line treatment.

J&J to pay $63M in Motrin case

A Massachusetts court upheld a 2013 decision that the drugmaker failed to provide sufficient risk information for Children's Motrin.

Five things for pharma marketers to know: Monday, April 20

Five things for pharma marketers to know: Monday, April 20

By

Teva eyes Mylan takeover; Keytruda shown to improve survival, shrink tumors in melanoma; ADHD abuse may follow grads into workforce.

Five things for pharma marketers to know: Thursday, April 16

Five things for pharma marketers to know: Thursday, April 16

By

FDA approves Amgen heart failure drug; Pfizer halts breast-cancer drug trial over positive results; 30% of study participants asked docs about drug after seeing or reading an ad

Biogen, PatientsLikeMe use Fitbit to better understand MS

Biogen, PatientsLikeMe use Fitbit to better understand MS

By

The drugmaker and patient network teamed up to establish a formal framework for deploying activity trackers for patients with MS and for capturing that data.

Five things for pharma marketers to know: Wednesday, April 15

Five things for pharma marketers to know: Wednesday, April 15

By

An FDA panel said heart risks should be part of Onglyza's label; the OIG will examine generic price increases; Abbott said its OTC glucose meter will save patients money

J&J reports quarterly boost in drug sales

J&J reports quarterly boost in drug sales

By

The company reported $7.7 billion in pharma revenue in the first quarter despite a drop in overall sales and profit.

GSK considering change to sales compensation model

The British drugmaker is reviewing the patient-oriented sales model it introduced in 2011.

Five things for pharma marketers to know: Monday, April 13

Five things for pharma marketers to know: Monday, April 13

By

Sanofi won't discount new insulin; Takeda appoints new US business head; insurers push back on expensive preventative genetic tests

Pfizer offers grants for PCSK9 research

The drugmaker is calling on researchers to investigate PCSK9s in specific areas of interest.

Doximity to launch Apple Watch app

The app for the smartwatch includes secure encrypted messaging.

Mylan plans to acquire OTC and generic drugmaker Perrigo

Generic giant Mylan proposed a deal valued at $30 billion to acquire Perrigo Company.

Hospira gets fifth FDA warning in two years

The company has received seven warning letters since 2010.

Five things for pharma marketers to know: Wednesday, April 8

Five things for pharma marketers to know: Wednesday, April 8

By

FDA accepts previously rejected Novo Nordisk insulin application; Merck HCV doublet regimen receives Breakthrough designation for patients with kidney disease; researchers say that rising costs for cancer drugs aren't reasonable

Five things for pharma marketers to know: Tuesday, April 7

Five things for pharma marketers to know: Tuesday, April 7

By

Merck funds protein-degrading technology; Shire expects approval for a new ADHD medication in 2017; state biosimilar notification laws focus on subtext

Rituxan may have rare-disease use

The cancer and immunology drug may help patients with a condition that affects two people in every one million.

FDA will study the impact prices have on Rx purchases

The study will include DTC and DTP advertising.

Five things for pharma marketers to know: Monday, April 6

Five things for pharma marketers to know: Monday, April 6

By

Pfizer exec said biosimilar interchangeability definition not happening anytime soon; AARP launches digital health tech studies with Pfizer and UnitedHealthcare; BMS inks gene therapy collaboration deal

Walgreen Co. sues Endo over pay-for-delay

Walgreen alleges Endo conspired to keep generic Opana ER off the market.

Teva concealed kickbacks in speaker program, former reps allege

Teva concealed kickbacks in speaker program, former reps allege

By

Two former Teva sales representatives claim the drugmaker used speaker programs to hide kickbacks for prescribing drugs Copaxone and Azilect.

Japan seeks more OTC medications

The government is asking consumers which ones they prefer.

FDA finalizes opioid guidance

Opioids lacking abuse-foiling technology will remain available.

Five things for pharma marketers to know: Wednesday, April 1

Five things for pharma marketers to know: Wednesday, April 1

By

Takeda proposes $2.2-billion settlement to resolve Actos suits; Public Citizen says diabetes drugs are unlawfully promoted; PAIN study says 20% to 30% of opioid drugs are misused

The 2015 healthcare agency questionnaire, for firms hoping to be featured in the Top 100 Agencies issue, is live. Click here to be considered.

Email Newsletters